Cargando…

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

ABSTRACT: INTRODUCTION: To assess the effect of canakinumab, a fully human anti-interleukin-1β antibody, on symptoms and health-related quality of life (HRQoL) in patients with cryopyrin-associated periodic syndrome (CAPS). METHODS: In this 48-week, phase 3 study, patients with CAPS received canakin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koné-Paut, Isabelle, Lachmann, Helen J, Kuemmerle-Deschner, Jasmin B, Hachulla, Eric, Leslie, Kieron S, Mouy, Richard, Ferreira, Alberto, Lheritier, Karine, Patel, Neha, Preiss, Ralph, Hawkins, Philip N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334655/ https://www.ncbi.nlm.nih.gov/pubmed/22152723 http://dx.doi.org/10.1186/ar3535

Ejemplares similares

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome
por: Elmi, Abdulkadir A., et al.
Publicado: (2019)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
por: Tilson, Hugh, et al.
Publicado: (2013)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
por: Lachmann, Helen J., et al.
Publicado: (2009)

P02-027 - Quality of life in CAPS treated by Canakinumab
por: Marsaud, C, et al.
Publicado: (2013)

Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response
por: Yu, Justin R., et al.
Publicado: (2010)

β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics
por: Kuemmerle-Deschner, J, et al.
Publicado: (2011)

Evidence based recommendations for diagnosis and treatment of cryopyrin-associated periodic syndromes (CAPS)
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Neurology of the Cryopyrin-Associated Periodic Feversyndrome
por: Parker, T, et al.
Publicado: (2015)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
por: Caorsi, Roberta, et al.
Publicado: (2013)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Live‐attenuated vaccines in a cryopyrin‐associated periodic syndrome patient receiving canakinumab treatment during infancy
por: Watanabe, Misa, et al.
Publicado: (2017)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome
por: Kuemmerle-Deschner, Jasmin Beate, et al.
Publicado: (2020)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

French Amyloidosis CAPS study: AA Amyloidosis complicating cryopyrin-associated periodic syndrome: a study on 14 cases and review of 53 cases from literature
por: Georgin-Lavialle, S, et al.
Publicado: (2015)

“Daily life of CAPS patients treated with canakinumab (Ilaris(®)) : data from the French observational study - ENVOL Study”
por: Koné-Paut, I, et al.
Publicado: (2015)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study
por: Mulders-Manders, Catharina M., et al.
Publicado: (2018)

The genetic and clinical characteristics and effects of Canakinumab on cryopyrin-associated periodic syndrome: a large pediatric cohort study from China
por: Shu, Zhou, et al.
Publicado: (2023)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System
por: Keddie, Stephen, et al.
Publicado: (2018)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome
por: Gorodetskiy, Vadim R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nfj22vac8ck7i21mausq64aij5